Pharmaceutical

Allied is committed to developing cutting-edge technology that focuses on treating mental illness, specifically targeted at PTSD and other forms of mental trauma for Veterans and First Responders.

Pharma Development Model

Allied Corp. Files First US Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder

On September 23, 2019, Allied announced the filing of its first United States Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder (PTSD).

This marks the first of a series of proposed filings, along with recent trademark filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy. This Pharma Development Strategy includes serving those suffering from mental health issues, with a particular focus on those suffering from symptoms related to PTSD.

The products developed under the Company’s IP&PD strategy are initially geared towards veterans and first responders and will further be available to anyone else suffering from symptoms related to PTSD. These products will be made available for sale under Allied’s recently launched natural health hemp-derived retail product line, TACTICAL RELIEF™.

“We are very excited to begin taking the strategic steps to developing and protecting our IP&PD strategy in the United States and around the world. Allied is committed to the development of a thoughtful and strategic Intellectual Property portfolio that is strengthened internationally by this filing.”
David Weinkauf, VP Pharma Development
“We are very excited to begin taking the strategic steps to developing and protecting our IP&PD strategy in the United States and around the world. Allied is committed to the development of a thoughtful and strategic Intellectual Property portfolio that is strengthened internationally by this filing.”
David Weinkauf, VP Pharma Development
“Currently, there are approximately 8 million people in the United States alone who suffer from symptoms related to PTSD. Although there are certain cognitive therapies that have proven to be helpful, there is no pharmaceutical drug that has an indication for this disease target. PTSD is a disorder that not only affects the person suffering, but his/her family and community as well. Through this patent filing, we have now taken the first step in our pharma development plan, as well as, protected our medical formulation that is focused on this disease target.”
Calum Hughes, CEO

Pre-clinical

  • Master Services Agreement with the University of Haifa, Israel via their wholly owned commercialization subsidiary: Carmel – Haifa University Economic Corporation Ltd. This world-class academic research center gives Allied access to a proprietary pre-clinical animal model that is owned by Carmel.
  • On September 23, 2019, Allied announced the filing of its first United States Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder (PTSD).
  • Intellectual property is owned by Allied Corp

Clinical

  • Late stage discussions with large Clinical Research Centres and Contract Research Organizations (CRO’s) for Clinical Trials
  • PHASE I clinical trial anticipated for Q3 2020
  • After completion of PHASE I, Allied intends to license to Big Pharma for commercialization

Sign up to our newsletter and get first access to the latest investor news, events, and other important information related to Allied Health.

Keep Informed